- Record: found
- Abstract: found
- Article: not found
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Gordon Hutchins
1 ,
Katie Southward ,
Kelly Handley ,
Laura Magill ,
Claire Beaumont ,
Jens Stahlschmidt ,
Susan Richman ,
Philip Chambers ,
Matthew Seymour ,
David Kerr ,
Richard Gray ,
Philip Quirke
Apr 01 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
It is uncertain whether modest benefits from adjuvant chemotherapy in stage II colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy.